company background image
SEQU

Sequana Medical ENXTBR:SEQUA Stock Report

Last Price

€5.72

Market Cap

€135.8m

7D

-6.8%

1Y

-33.2%

Updated

13 May, 2022

Data

Company Financials +
SEQUA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

SEQUA Stock Overview

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure.

Sequana Medical Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Sequana Medical
Historical stock prices
Current Share Price€5.72
52 Week High€9.80
52 Week Low€5.26
Beta1.14
1 Month Change-12.27%
3 Month Change-11.46%
1 Year Change-33.18%
3 Year Change-7.14%
5 Year Changen/a
Change since IPO-32.07%

Recent News & Updates

Shareholder Returns

SEQUABE Medical EquipmentBE Market
7D-6.8%1.3%-1.0%
1Y-33.2%-11.3%-4.6%

Return vs Industry: SEQUA underperformed the Belgian Medical Equipment industry which returned -12.6% over the past year.

Return vs Market: SEQUA underperformed the Belgian Market which returned -3.6% over the past year.

Price Volatility

Is SEQUA's price volatile compared to industry and market?
SEQUA volatility
SEQUA Average Weekly Movement7.1%
Medical Equipment Industry Average Movement7.5%
Market Average Movement5.1%
10% most volatile stocks in BE Market8.0%
10% least volatile stocks in BE Market3.2%

Stable Share Price: SEQUA is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SEQUA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
200660Ian Crosbiehttps://www.sequanamedical.com

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company’s products include alfapump system, an implantable pump system for the treatment of refractory ascites due to liver cirrhosis and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal (DSR) to manage fluid overload in heart failure patients. It operates in Switzerland, Germany, France and internationally.

Sequana Medical Fundamentals Summary

How do Sequana Medical's earnings and revenue compare to its market cap?
SEQUA fundamental statistics
Market Cap€135.83m
Earnings (TTM)-€23.62m
Revenue (TTM)€370.50k

366.7x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SEQUA income statement (TTM)
Revenue€370.50k
Cost of Revenue€76.66k
Gross Profit€293.84k
Other Expenses€23.91m
Earnings-€23.62m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 08, 2022

Earnings per share (EPS)-0.99
Gross Margin79.31%
Net Profit Margin-6,373.84%
Debt/Equity Ratio-930.8%

How did SEQUA perform over the long term?

See historical performance and comparison

Valuation

Is Sequana Medical undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Sequana Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sequana Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Sequana Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-4.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SEQUA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SEQUA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SEQUA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SEQUA's revenue (75.5% per year) is forecast to grow faster than the Belgian market (0.7% per year).

High Growth Revenue: SEQUA's revenue (75.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SEQUA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sequana Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SEQUA is currently unprofitable.

Growing Profit Margin: SEQUA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SEQUA is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare SEQUA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SEQUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.1%).


Return on Equity

High ROE: SEQUA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Sequana Medical's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SEQUA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SEQUA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SEQUA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: SEQUA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SEQUA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SEQUA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.4% each year


Dividend

What is Sequana Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SEQUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SEQUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SEQUA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SEQUA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SEQUA has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Ian Crosbie

6.33yrs

Tenure

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...


Leadership Team

Experienced Management: SEQUA's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: SEQUA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.8%.


Top Shareholders

Company Information

Sequana Medical NV's employee growth, exchange listings and data sources


Key Information

  • Name: Sequana Medical NV
  • Ticker: SEQUA
  • Exchange: ENXTBR
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €135.830m
  • Shares outstanding: 23.75m
  • Website: https://www.sequanamedical.com

Number of Employees


Location

  • Sequana Medical NV
  • AA Tower
  • Technologiepark 122
  • Gent
  • East Flanders
  • 9052
  • Belgium

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/13 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.